Companies /Healthcare

Lite Strategy, Inc.

NASDAQ: LITS Biotechnology

LITS at a Glance

Valuation
Market cap
$35.0M
Profitability
EPS (TTM)
$-2.06
Price
52-week range
$1 – $2
Earnings
Next report
Nov 13, 2026

Headquartered in San Diego, CA Fiscal year ends June NASDAQ: LITS litestrategy.com

About Lite Strategy

Lite Strategy, Inc. (Nasdaq: LITS) is a U.S. publicly traded company that has adopted Litecoin (LTC) as its primary treasury reserve asset. The company employs an active treasury management strategy, including a covered call options program, to generate yield on its Litecoin holdings. Lite Strategy aims to offer investors regulated, transparent, and actively managed exposure to Litecoin that differentiates it from ETFs or passive investment vehicles. The company also maintains a portfolio of pharmaceutical assets focused on pre-clinical development programs in non-oncology disease indications, which it views as potential sources of non-dilutive capital through out-licensing or sale. The company currently generates no product revenue. Updated

LITS Coverage

8:00am ET
Cryptocurrency

Litecoin Just Turned 15. Has It Kept Up With Bitcoin?

Fifteen years after launching as Bitcoin's faster, cheaper sibling, Litecoin faces a hard question about whether it has grown into its own or simply fallen behind. The 2027 halving looms as a…

Sam Daodu

Frequently Asked Questions

What does Lite Strategy do?

Lite Strategy, Inc. (Nasdaq: LITS) is a U.S. publicly traded company that has adopted Litecoin (LTC) as its primary treasury reserve asset. The company employs an active treasury management strategy, including a covered call options program, to generate yield on its Litecoin holdings.